AIM ImmunoTech Inc.

About AIM ImmunoTech Inc.

AIM ImmunoTech is a biotechnology company focused on advancing therapeutic solutions through immunology for a better future. The company aims to develop innovative treatments to improve lives across various disease areas, including oncology, immune disorders, and viral diseases.

Products & Services

Ampligen(r):An immuno-modulator with broad spectrum activity shown in in-vitro and animal testing, currently being evaluated in clinical studies for a range of debilitating and life-threatening conditions.

Ampligen®

Specialties

Immunology Immuno-Oncology Immune Disorders Viral Diseases immuno-modulation oncology immune disorders viral diseases

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Registered Direct Offering and Private Placement T: - FT: Registered Direct Offering and Private Placement	A: 2650000 MR: - FA: $2.65 million FAN: 2650000	D: 2026-06-09 FD: 2026-06-09	-
2	RT: Registered Direct Offering and Private Placement T: - FT: Registered Direct Offering and Private Placement	A: 2400000 MR: - FA: $2.4 million FAN: 2400000	D: 2026-05-20 FD: 2026-05-20	-
3	RT: Warrant Exercise T: - FT: Warrant Exercise	A: 4200000 MR: - FA: approximately $4.2 million FAN: 4200000	D: 2026-05-08 FD: 2026-05-08	1 investors
4	RT: Rights Offering T: - FT: Rights Offering	A: 1800000 MR: - FA: approximately $1.8 million FAN: 1800000	D: 2026-03-06 FD: 2026-03-06	-
5	RT: Rights Offering T: - FT: Rights Offering	A: 1800000 MR: - FA: 1.8 Million FAN: 1800000	D: 2026-03-04 FD: 2026-03-04	1 investors
6	RT: Rights Offering T: - FT: Rights Offering	A: 12000000 MR: - FA: $12,000,000 FAN: 12000000	D: 2026-02-12 FD: 2026-02-12	-
7	RT: Rights Offering T: - FT: Rights Offering	A: 12000000 MR: - FA: 12 million FAN: 12000000	D: 2026-02-11 FD: 2026-02-11	1 investors
8	RT: Rights Offering T: - FT: Rights Offering	A: 12000000 MR: - FA: 12 million FAN: 12000000	D: 2026-01-23 FD: 2026-01-23	1 investors
9	RT: Public Offering T: - FT: Public Offering	A: 8000000 MR: - FA: $8.0 Million FAN: 8000000	D: 2025-07-31 FD: 2025-07-31	-
10	RT: Public Offering T: - FT: Public Offering	A: 8000000 MR: - FA: 8.0 million FAN: 8000000	D: 2025-07-29 FD: 2025-07-29	1 investors
11	RT: Registered Direct Offering and Private Placement T: - FT: Registered Direct Offering and Private Placement	A: 1260000 MR: - FA: approximately $1.26 million FAN: 1260000	D: 2024-09-30 FD: 2024-09-30	1 investors
12	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 2000000 MR: - FA: $2.0 million FAN: 2000000	D: 2024-05-31 FD: 2024-05-31	1 investors

Registered Direct Offering and Private Placement Latest

2026-06-09

$2.6M

Registered Direct Offering and Private Placement 2026-05-20

$2.4M

Warrant Exercise 2026-05-08

$4.2M

View 11 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

T

Thomas K Equels

Chief Executive Officer, President & Executive Vice Chairman

P

Peter W. Rodino III

Chief Operating Officer, Executive Director for Governmental Relations, General Counsel, Secretary

R

Robert Dickey IV

Chief Financial Officer

C

Charles Lapp

Consulting Medical Officer

C

Christopher Nicodemus

Consulting Science Officer

W

William M. Mitchell

Chairman of the Board

View 13 more team members with Pro

Unlock Full Team Directory

Recent News